Ramaswamy's Roivant Inks $650M R&D Deal With This Tiny Diabetes Biotech Post author:Sam Post published:February 11, 2018 Post category:BioPharma With the deal in hand, Roivant has stepped into the world of metabolic diseases. Source: BioSpace You Might Also Like Two Bay Area Diagnostic Companies Win Amgen's Golden Ticket July 11, 2017 GlaxoSmithKline Gets Expanded FDA Win for Fluarix January 11, 2018 <b>Vicarius Pharma</b> Launches With $21.8 Million and Will be Helmed by Former Biogen-Elan Exec August 13, 2017
<b>Vicarius Pharma</b> Launches With $21.8 Million and Will be Helmed by Former Biogen-Elan Exec August 13, 2017
